Research Paper Volume 15, Issue 16 pp 8090—8112
Identification of immunotherapy biomarkers for improving the clinical outcome of homologous recombination deficiency patients with lung adenocarcinoma
Figure 8. Construction and validation of MS4A6A-based immunotherapy predictive model. (A) ROC curves for MS4A6A, PD-1, PD-L1, and CTLA4 based on the GSE126044 cohort. (B) ROC curves for TMB, MS4A6A, PD-1, PD-L1, and CTLA4 based on the IMvigor210 cohort. (C) Immunotherapy prediction model nomogram. (D) Calibration curves of the immunotherapy prediction model. (E) Comparison of prediction accuracy of immunotherapy model with and without MS4A6A. (F) Clinical decision curves of the immunotherapy prediction model. (G) The ROC curve of clinical model (AUC = 0.774).